CHICAGO – Merck KGaA deepened its relationship with F-star Biotechnology Ltd., begun in 2010, by way of a new pact to develop and commercialize five bispecific immuno-oncology antibodies in an arrangement that could be worth about €1 billion (US$1.12 billion) if the pharma giant likes what it sees in a data package yet to come.